Design Therapeutics (DSGN) announced that the first Friedreich ataxia, FA, patient has been dosed via intravenous infusion in its RESTORE-FA open-label Phase 1/2 multiple-ascending dose clinical trial of DT-216P2. The RESTORE-FA trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IV and subcutaneous administration of DT-216P2 in patients with FA. DT-216P2 has been administered in one patient to date with no adverse events reported, including no injection site thrombophlebitis. The trial is currently open for enrollment in Australia. Design anticipates reporting data from the MAD trial, including levels of frataxin expression based on 12 weeks of dosing, in 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics files $300M mixeds securities shelf
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
- Design Therapeutics announces data from Phase 1 SAD/MAD trial of DT-168
- RBC sees Makary interview as potentially positive for biotech stocks